Study Title
A Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
Study Details
Description:
This study is Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
Sponsor:
Perspective TherapeuticsContacts:
Markus Puhlmann, MD, MBAmpuhlmann@perspectivetherapeutics.com
(319) 665-2150
Government Study Link:
NCT05636618 - Click here to see study onClinicalTrials.gov
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations